抗淀粉样蛋白-β 抗体药物，如治疗阿尔茨海默病的新药 Recanemab，正吸引着人们对其商业化的高度期待。 另一方面，淀粉样蛋白相关成像异常（ARIA）在安全性方面可能导致的不良反应，也为创造一个可安全处方这些药物的环境带来了挑战。 本期，我们将为您介绍中文版的淀粉样蛋白相关成像异常及相关评估标准。
Category
Please feel free to contact us
We provide comprehensive, end‑to‑end clinical development support, with imaging at its core.
With more than 20 years of experience, our team of imaging specialists in Japan and around the world tackles the complex challenges of imaging evaluation in pharmaceutical and medical device development. We deliver optimal, project‑specific solutions for each client.